Table 2.
Overall and progression free survival—univariate analysis.
| Characteristics | No (%) | PFS | OS |
|---|---|---|---|
| p-value | p-value | ||
| Performance status | |||
| 0–2 | 103 (83) | 0.007 | 0.0012 |
| 3–4 | 21 (17) | ||
| CS | |||
| I/II | 77 (62) | 0.001 | 0.0010 |
| III/IV | 47 (38) | ||
| CS | |||
| I–III | 87 (70) | 0.00009 | 0.00007 |
| IV | 37 (30) | ||
| LDH | |||
| Normal | 18 (14.5) | 0.16 | 0.20 |
| Elevated | 106 (85.6) | ||
| Pericardial effusion | |||
| No | 88 (71) | 0.04 | 0.05 |
| Yes | 36 (29) | ||
| Pleural effusion | |||
| No | 82 (66) | 0.36 | 0.92 |
| Yes | 42 (34) | ||
| Extranodal site > 1 | |||
| No | 120 (97) | 0.003 | 0.0007 |
| Yes | 4 (3) | ||
| IPI | |||
| 0–2 | 94 (76) | 0.001 | 0.0018 |
| 3–5 | 30 (24) | ||
| Radiotherapy at CS I–III | |||
| No | 16 (19) | 0.23 | 0.64 |
| Yes | 68 (81) | ||
CS clinical stage, IPI international prognostic index, LDH dehydrogenase lactate, No number, OS overall survival, PFS progression free survival.